Medicinova (MNOV) FCF Margin (2012 - 2025)

Medicinova's (MNOV) quarterly FCF Margin came in at 1329.12% in Q4 2025, up 3.77% on a QoQ basis from 1381.13% in Q3 2025.

Medicinova (MNOV) FCF Margin (2012 - 2025) Analysis & Trends

Medicinova (MNOV) has 5 years of FCF Margin data on file, last reported at 1329.12% in Q4 2025.

On a quarterly basis, FCF Margin changed N/A year-over-year to 1329.12% in Q4 2025; TTM through Dec 2025 was 2394.7%, a N/A change from a year earlier, with the FY2025 full-year figure at 2395.41%, changed N/A from the prior year.
FCF Margin for Q4 2025 stood at 1329.12%, up from 1381.13% in the prior quarter.
Over the last five years, FCF Margin for MNOV reached as high as 96.35% in Q1 2021 and fell as low as 8049.5% in Q3 2021.
Historically, FCF Margin has averaged 2117.84% across 3 years, with a median of 1355.13% in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	10.45%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.53%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Medicinova	64.48 Mn	64.48 Mn	4,754.00	-1,329.12%

Download Data